Francois Chomy
Overview
Explore the profile of Francois Chomy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bessede A, Peyraud F, Besse B, Cousin S, Cabart M, Chomy F, et al.
Clin Cancer Res
. 2023 Dec;
30(4):779-785.
PMID: 38048058
Purpose: Mechanisms of primary resistance to inhibitors of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling axis in non-small cell lung cancer (NSCLC) are still poorly understood. While some...
2.
Mottet T, Hemar V, Enfedaque S, Mathoulin-Pelissier S, Charitansky H, Godbert Y, et al.
Acta Oncol
. 2023 Nov;
62(12):1905-1912.
PMID: 37948066
Introduction: Integrating telemedicine into cancer care remains a major challenge. There are little clinical evidence for teleconsultation efficacy and safety in daily oncology practice. This study as a pioneering experience,...
3.
Bessede A, Peyraud F, Moulec S, Cousin S, Cabart M, Chomy F, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4883-4893.
PMID: 37756581
Purpose: Overexpression of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) has been reported in several tumor types, including non-small cell lung cancer (NSCLC), and has been shown to promote tumor-immune...
4.
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, et al.
Clin Cancer Res
. 2022 Jul;
28(18):4018-4026.
PMID: 35802649
Purpose: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized the approach to non-small cell lung cancer (NSCLC) treatment in the era of precision medicine. Their impact as switch...
5.
Bechade D, Bellera C, Gauquelin L, Soubeyran I, McKelvie-Sebileau P, Debled M, et al.
Clin Res Hepatol Gastroenterol
. 2022 Mar;
46(5):101912.
PMID: 35341993
Background: The high sensitivity of PET-CT can identify hypermetabolic mediastinal adenopathies during cancer management, but specificity is low and a biopsy is sometimes required to eliminate benign adenopathies. Methods: This...
6.
Vanhersecke L, Brunet M, Guegan J, Rey C, Bougouin A, Cousin S, et al.
Nat Cancer
. 2022 Feb;
2(8):794-802.
PMID: 35118423
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types....
7.
Collin A, Groza V, Missenard L, Chomy F, Colin T, Palussiere J, et al.
Bull Math Biol
. 2021 May;
83(6):68.
PMID: 33966172
Non-small-cell lung carcinoma is a frequent type of lung cancer with a bad prognosis. Depending on the stage and genomics, several therapeutical approaches are used. Tyrosine Kinase Inhibitors (TKI) may...
8.
Palussiere J, Catena V, Lagarde P, Cousin S, Cabart M, Buy X, et al.
Int J Hyperthermia
. 2019 Sep;
36(2):46-52.
PMID: 31537155
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for...
9.
Palussiere J, Lagarde P, Auperin A, Deschamps F, Chomy F, De Baere T
Cardiovasc Intervent Radiol
. 2014 Nov;
38(1):160-6.
PMID: 25394595
Purpose: To evaluate the survival outcomes of percutaneous thermal ablation (RFA + microwaves) for patients presenting N0 non-small-cell lung cancer (NSCLC) ineligible for surgery. Materials And Methods: Eighty-seven patients from...
10.
Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, Blanc J, Dauba J, et al.
PLoS One
. 2014 Sep;
9(9):e108687.
PMID: 25265392
Objective: We tested the effect of dietary advice dedicated to increase intake in older patients at risk for malnutrition during chemotherapy, versus usual care, on one-year mortality. Method: We conducted...